Name : Human EPO/Erythropoietin Protein
Product Source :
Recombinant Human EPO/Erythropoietin Protein is expressed from HEK293 without tag. It contains Ala28-Arg193.[Accession | AAH93628.1]
Molecular Weight :
The protein has a predicted MW of 18.39 kDa. Due to glycosylation, the protein migrates to 35-45 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human EPO on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human EPO is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human EPO, No Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human EPO R, hFc Tag with the EC50 of 29.7ng/ml determined by ELISA. Cell Based Assay Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.4 ‑ 1 ng/mL (QC Test).
Background :
Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects.
Synonyms :
EPO; Erythropoietin; EP; MVCD2; Epoetin
References & Citations :
Lin TY, Lai YF, Chen YH, Lu DW. The Latest Evidence of Erythropoietin in the Treatment of Glaucoma. Int J Mol Sci. 2022 Dec 16;23(24):16038. doi: 10.3390/ijms232416038. PMID: 36555679; PMCID: PMC9784015.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CD14 Proteinmanufacturer
FGFR-4 ProteinFormulation
Popular categories:
CD266/TWEAK R
Calcitonin